Abstract
Parkinson's disease (PD) is a neurodegenerative disorder orphan of valuable therapies. PD is neuropathological characterized by intracellular Lewy bodies formed by aggregated α-synuclein (α-syn ) in mesencephalic region and neuroinflammation significantly contribute to the pathogenesis of the disease. In the complex scenario of PD single target therapy cannot be beneficial, a therapeutic strategy simultaneously affecting α-syn aggregation and neuroinflammation may be useful to affect PD progression. Recently, the antimicrobial drug Doxycycline (Doxy) has been demonstrated to inhibit α-syn aggregation. In addition, we have reported that Doxy at sub-antibiotic doses efficiently counteracts memory impairment and neuroinflammation in a transgenic (Tg) mouse model of Alzheimer's Disease. Based on the multiple action mechanism of Doxy, we herein investigate the potential therapeutic properties of Doxy in a Tg PD mouse model.A53T mice and their non-Tg (NTG) litter mates were intraperitoneally treated with 10mg/Kg Doxy for 30 days. At the end of treatment, cognitive and motor performances were evaluated in the Novel object recognition test (NORT), Nesting test, Beam-walk and Paw grip endurance. In addition, hippocampal long term potentiation (LTP) was assessed. Neuropathological markers were explored through immunohistological and biochemical approaches.Doxy abolished the cognitive deficit in the NORT. Moreover, Doxy restored daily life activity of A53T mice in the Nesting test, which is dependent by hippocampal and cortical networks. Aside from an effect at cognitive level, we found that Doxy treatment ameliorated motor performances in both the Beam-walk test and in the Paw grip endurance. The effect on cognitive functions was strictly linked to a reduced neuronal loss in the cortex and hippocampus of A53T+Doxy compared to A53T+Veh group. Moreover, glial activation were blocked by our pharmacological approach both in the cortex and hippocampus. In addition, Doxy treatment restored hippocampal LTP in association with the dampening of pro-inflammatory cytokines expression.Doxy emerges as a valuable therapeutic approach to counteract both symptoms and neuropathological hallmarks in the complex scenario of a Tg PD mouse model. Moreover, our results depict PD as a novel field for repurposing Doxy and corroborate previous data indicating Doxy as a multi-target drug.
Highlights
Parkinson’s disease remains orphan of valuable therapies capable to interfere with the disease pathogenesis despite the large number of symptomatic approaches adopted in clinical practice to manage this disease
We hypothesized that a therapeutic approach based on a single molecule affecting at the same time α-syn aggregation and neuroinflammation may offer a promising tool to alleviate Parkinson’s Disease (PD) progression
Our results demonstrate that the treatment with Doxy at sub-antimicrobial dose leads to beneficial effects in A53T mice
Summary
Parkinson’s disease remains orphan of valuable therapies capable to interfere with the disease pathogenesis despite the large number of symptomatic approaches adopted in clinical practice to manage this disease. Treatments simultaneously affecting α-synuclein (α-syn) oligomerization and neuroinflammation may counteract Parkinson’s disease. Recent data demonstrated that Doxycycline an antibiotic of the tetracycline class, can inhibit α-syn aggregation and exert anti-inflammatory activity. For the first time, the potential therapeutic properties of Doxy in a human α-syn A53T transgenic Parkinson’s disease mouse model by the evaluation of behavioural, biochemical and histopathological parameters
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
